Division of Endocrinology, Diabetes and Bone Diseases, Mount Sinai School of Medicine, Box No. 1055, One Gustave L. Levy Place, New York, NY 10029, USA.
Trends Endocrinol Metab. 2010 Oct;21(10):610-8. doi: 10.1016/j.tem.2010.06.007. Epub 2010 Jul 19.
Epidemiological studies have reported an increased risk of cancer in people with type 2 diabetes (T2DM) and obesity, related in part to hyperinsulinemia, secondary to insulin resistance. Hyperinsulinemia leads to increased expression of insulin-like growth factor (IGF)-I expression. In fact, increased insulin, IGF-I and IGF-II levels are associated with tumor growth in vitro, in animal models, and in epidemiological studies in humans. In this paper, we discuss the roles of insulin, IGF-I and IGF-II, their interaction with the insulin receptor (IR) and IGF-I receptor (IGF-IR), and their signaling pathways and regulation as these pertain to tumor growth. We explain how these pathways have been deciphered by in vitro and in vivo studies, and how they are being exploited in the development of targeted cancer therapies.
流行病学研究报告表明,2 型糖尿病(T2DM)和肥胖患者的癌症风险增加,部分原因与胰岛素抵抗导致的高胰岛素血症有关。高胰岛素血症导致胰岛素样生长因子(IGF)-I 的表达增加。事实上,体外、动物模型和人类流行病学研究均表明,胰岛素、IGF-I 和 IGF-II 水平的升高与肿瘤生长有关。在本文中,我们讨论了胰岛素、IGF-I 和 IGF-II 的作用,它们与胰岛素受体(IR)和 IGF-I 受体(IGF-IR)的相互作用,以及它们的信号通路和调节,这些都与肿瘤生长有关。我们解释了这些途径如何通过体外和体内研究来阐明,以及它们如何在靶向癌症治疗的开发中得到利用。